Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease

Journal of Lipid Research

Volumn 54, Issue 10, 2013, Pages 2884-2897

  Fonteh, Alfred N ^a   Chiang, Jiarong ^a   Cipolla, Matthew ^a   Hale, Jack ^a   Diallo, Fatimatou ^a   Chirino, Alejandra ^a   Arakaki, Xianghong ^a   Harrington, Michael G ^a  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

Lipid metabolism; Liquid chromatography; Mass spectrometry; Minimal cognitive impairment; Nanoparticles; Neurodegeneration

Indexed keywords

1 RADYL 2 ACYL GLYCEROPHOSPHOCHOLINE; 1 RADYL 2 ACYL GLYCEROPHOSPHOETHANOLAMINE; 1,2 DIACYL GLYCEROPHOSPHOSERINE; GLYCEROPHOSPHOETHANOLAMINE; GLYCEROPHOSPHOLIPID; GLYCEROPHOSPHORYLCHOLINE; LYSOPHOSPHATIDYLCHOLINE; MONOUNSATURATED FATTY ACID; N ACYL PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPASE A2; PHOSPHOSERINE; PLATELET ACTIVATING FACTOR LIKE LIPID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; ENZYME ACTIVITY; FEMALE; FRACTIONATION; HUMAN; LIPID COMPOSITION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUPERNATANT; TANDEM MASS SPECTROMETRY;

LIPID METABOLISM; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MINIMAL COGNITIVE IMPAIRMENT; NANOPARTICLES; NEURODEGENERATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; GLYCEROPHOSPHOLIPIDS; HUMANS; LIPID METABOLISM; MALE; PHOSPHOLIPASES A2; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84884142152     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M037622     Document Type: Article

References (53)

1. Fahy, E., S. Subramaniam, R. C. Murphy, M. Nishijima, C. R. Raetz, T. Shimizu, F. Spener, G. van Meer, M. J. Wakelam, and E. A. Dennis. 2009. Update of the LIPID MAPS comprehensive classifi- cation system for lipids. J. Lipid Res. 50 (Suppl.) : S9 - S14.
2. Adibhatla, R. M., and J. F. Hatcher. 2008. Altered lipid metabolism in brain injury and disorders. Subcell. Biochem. 49: 241-268.
3. Bazan, N. G. 2005. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol. Neurobiol. 32: 89-103.
4. Fonteh, A. N., R. J. Harrington, A. F. Huhmer, R. G. Biringer, J. N. Riggins, and M. G. Harrington. 2006. Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis. Markers. 22: 39-64.
5. Piomelli, D., G. Astarita, and R. Rapaka. 2007. A neuroscientist's guide to lipidomics. Nat. Rev. Neurosci. 8: 743-754.
6. Rapoport, S. I. 2001. In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling. J. Mol. Neurosci. 16: 243-261.
7. Kramer, R. M., J. A. Jakubowski, and D. Deykin. 1988. Hydrolysis of 1-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine, a common precursor of platelet-activating factor and eicosanoids, by human platelet phospholipase A 2. Biochim. Biophys. Acta. 959: 269-279.
8. Farooqui, A. A., and L. A. Horrocks. 2004. Brain phospholipases A 2: a perspective on the history. Prostaglandins Leukot. Essent. Fatty Acids. 71: 161-169.
9. Six, D. A., and E. A. Dennis. 2000. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim. Biophys. Acta. 1488: 1-19.
10. Khaselev, N., and R. C. Murphy. 1999. Susceptibility of plasmenyl glycerophosphoethanolamine lipids containing arachidonate to oxidative degradation. Free Radic. Biol. Med. 26: 275-284.
11. Jonas, A. 2000. Lecithin cholesterol acyltransferase. Molecular and Cell Biology of Lipids. 1529: 245-256.
12. Astarita, G., and D. Piomelli. 2009. Lipidomic analysis of endocannabinoid metabolism in biological samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877: 2755-2767.
13. Basavarajappa, B. S. 2007. Critical enzymes involved in endocannabinoid metabolism. Protein Pept. Lett. 14: 237-246.
14. Piomelli, D., A. Giuffrida, A. Calignano, and F. F. Rodriguez De. 2000. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. 21: 218-224.
15. Wang, J., and N. Ueda. 2009. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat. 89: 112-119.
16. Tyurina, Y. Y., A. Shvedova, K. Kawai, V. A. Tyurin, C. Kommineni, P. Quinn, N. Schor, J. Fabisiak, and V. Kagan. 2000. Phospholipid signaling in apoptosis: peroxidation and externalization of phosphatidylserine. Toxicology. 148: 93-101.
17. Farooqui, A. A., L. Liss, and L. A. Horrocks. 1988. Neurochemical aspects of Alzheimer's disease: involvement of membrane phospholipids. Metab. Brain Dis. 3: 19-35.
18. Kosicek, M., and S. Hecimovic. 2013. Phospholipids and Alzheimer's disease: alterations, mechanisms and potential biomarkers. Int. J. Mol. Sci. 14: 1310-1322.
19. Söderberg, M., C. Edlund, K. Kristensson, and G. Dallner. 1991. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids. 26: 421-425.
20. Farooqui, A. A., and L. A. Horrocks. 1998. Plasmalogen-selective phospholipase A 2 and its involvement in Alzheimer's disease. Biochem. Soc. Trans. 26: 243-246.
21. Gattaz, W. F., O. V. Forlenza, L. L. Talib, N. R. Barbosa, and C. M. Bottino. 2004. Platelet phospholipase A 2 activity in Alzheimer's disease and mild cognitive impairment. J. Neural Transm. 111: 591-601.
22. Ross, B. M., A. Moszczynska, J. Erlich, and S. J. Kish. 1998. Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A 2 activity. J. Neurochem. 70: 786-793.
23. Stephenson, D. T., C. A. Lemere, D. J. Selkoe, and J. A. Clemens. 1996. Cytosolic phospholipase A 2 (cPLA 2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol. Dis. 3: 51-63.
24. Harrington, M. G., A. N. Fonteh, E. Oborina, P. Liao, R. P. Cowan, G. McComb, J. N. Chavez, J. Rush, R. G. Biringer, and A. F. Huhmer. 2009. The morphology and biochemistry of nanostructures provide evidence for synthesis and signaling functions in human cerebrospinal fluid. Cerebrospinal Fluid Res. 6: 10.
25. McKhann, G. M., D. S. Knopman, H. Chertkow, B. T. Hyman, C. R. Jack, Jr., C. H. Kawas, W. E. Klunk, W. J. Koroshetz, J. J. Manly, R. Mayeux, et al. 2011. The diagnosis of dementia due to Alzheimer's disease: recommendation from the National Institute on Aging Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 77: 263-269.
26. Morris, J. C. 1997. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int. Psychogeriatr. 9 (Suppl. 1) : 173-176.
27. Petersen, R. C. 2004. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256: 183-194.
28. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
29. Murphy, R. C. 2002. Mass Spectrometry of Phospholipids: Tables of Molecular and Product Ions. Illuminati Press, Denver, CO.
30. Harrison, K. A., S. S. Davies, G. K. Marathe, T. McIntyre, S. Prescott, K. M. Reddy, J. R. Falck, and R. C. Murphy. 2000. Analysis of oxidized glycerophosphocholine lipids using electrospray ionization mass spectrometry and microderivatization techniques. J. Mass Spectrom. 35: 224-236.
31. Marathe, G. K., S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. 2001. Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc. Med. 11: 139-142.
32. Huang, Z., F. Laliberte, N. M. Tremblay, P. K. Weech, and I. P. Street. 1994. A continuous fluorescence-based assay for the human high-molecular- weight cytosolic phospholipase A 2. Anal. Biochem. 222: 110-115.
33. Huhmer, A. F., R. G. Biringer, H. Amato, A. N. Fonteh, and M. G. Harrington. 2006. Protein analysis in human cerebrospinal fluid: physiological aspects, current progress and future challenges. Dis. Markers. 22: 3-26.
34. Han, X., and R. W. Gross. 2005. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 24: 367-412.
35. Milne, S., P. Ivanova, J. Forrester, and B. H. Alex. 2006. Lipidomics: an analysis of cellular lipids by ESI-MS. Methods. 39: 92-103.
36. Zhao, Y. Y., Y. Xiong, and J. M. Curtis. 2011. Measurement of phospholipids by hydrophilic interaction liquid chromatography coupled to tandem mass spectrometry: the determination of choline containing compounds in foods. J. Chromatogr. A. 1218: 5470-5479.
37. Reis, A., and C. M. Spickett. 2012. Chemistry of phospholipid oxidation. Biochim. Biophys. Acta. 1818: 2374-2387.
38. Wellner, N., T. A. Diep, C. Janfelt, and H. S. Hansen. 2013. N-acylation of phosphatidylethanolamine and its biological functions in mammals. Biochim. Biophys. Acta. 1831: 652-662.
39. Ueda, N., K. Tsuboi, and T. Uyama. 2010. Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim. Biophys. Acta. 1801: 1274-1285.
40. Simon, G. M., and B. F. Cravatt. 2006. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J. Biol. Chem. 281: 26465-26472.
41. Davidson, J. E., A. Lockhart, L. Amos, H. A. Stirnadel-Farrant, V. Mooser, M. Sollberger, A. Regeniter, A. U. Monsch, and M. C. Irizarry. 2012. Plasma lipoprotein-associated phospholipase A 2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study. Alzheimers Res. Ther. 4: 51.
42. Amtul, Z., M. Uhrig, R. Supino, and K. Beyreuther. 2010. Phospholipids and a phospholipid-rich diet alter the in vitro amyloid-beta peptide levels and amyloid-beta 42/40 ratios. Neurosci. Lett. 481: 73-77.
43. Grimm, M. O., V. J. Haupenthal, T. L. Rothhaar, V. C. Zimmer, S. Grosgen, B. Hundsdorfer, J. Lehmann, H. S. Grimm, and T. Hartmann. 2013. Effect of different phospholipids on alphasecretase activity in the non-amyloidogenic pathway of Alzheimer's disease. Int. J. Mol. Sci. 14: 5879-5898.
44. Sundaram, J. R., E. S. Chan, C. P. Poore, T. K. Pareek, W. F. Cheong, G. Shui, N. Tang, C. M. Low, M. R. Wenk, and S. Kesavapany. 2012. Cdk5/p25-induced cytosolic PLA 2 -mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration. J. Neurosci. 32: 1020-1034.
45. Desbène, C., C. Malaplate-Armand, I. Youssef, P. Garcia, C. Stenger, M. Sauvee, N. Fischer, D. Rimet, V. Koziel, M. C. Escanye, et al. 2012. Critical role of cPLA 2 in Abeta oligomer-induced neurodegeneration and memory deficit. Neurobiol. Aging. 33: 1123. e17-1129.e29.
46. Bazan, N. G., M. F. Molina, and W. C. Gordon. 2011. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu. Rev. Nutr. 31: 321-351.
47. Cummings, J. L. 2001. Treatment of Alzheimer's disease. Clin. Cornerstone. 3: 27-39.
48. Kidd, P. M. 2008. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern. Med. Rev. 13: 85-115.
49. Lemkul, J. A., and D. R. Bevan. 2011. Lipid composition influences the release of Alzheimer's amyloid beta-peptide from membranes. Protein Sci. 20: 1530-1545.
50. Yang, X., W. Sheng, Y. He, J. Cui, M. A. Haidekker, G. Y. Sun, and J. C. Lee. 2010. Secretory phospholipase A 2 type III enhances alphasecretase- dependent amyloid precursor protein processing through alterations in membrane fluidity. J. Lipid Res. 51: 957-966.
51. Coulon, D., L. Faure, M. Salmon, V. Wattelet, and J. J. Bessoule. 2012. Occurrence, biosynthesis and functions of N-acylphosphatidylethanolamines (NAPE): not just precursors of N-acyletha nolamines (NAE). Biochimie. 94: 75-85.
52. Farooqui, A. A., M. L. Litsky, T. Farooqui, and L. A. Horrocks. 1999. Inhibitors of intracellular phospholipase A 2 activity: their neurochemical effects and therapeutical importance for neurological disorders. Brain Res. Bull. 49: 139-153.
53. Farooqui, A. A., W. Y. Ong, and L. A. Horrocks. 2004. Neuroprotection abilities of cytosolic phospholipase A 2 inhibitors in kainic acid-induced neurodegeneration. Curr. Drug Targets Cardiovasc. Haematol. Disord. 4: 85-96.